Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management·2014

Same author

Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management·2014

Same author

Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management·2014

Same author

Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management·2014

Same author

Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management·2014

Same author

Pharmaceutical approval update.

P & T : a peer-reviewed journal for formulary management·2014

Search research articles

Related Experiment Video

Updated: May 19, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Pharmaceutical approval update.

Marvin M Goldenberg

P & T : a Peer-Reviewed Journal for Formulary Management

|August 10, 2012

Summary

This summary is machine-generated.

New treatments for acne, heavy menstrual bleeding, and Gaucher

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: May 19, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Area of Science:

Dermatology, Reproductive Endocrinology, and Genetic Medicine.

Background:

Acne, heavy menstrual bleeding (HMB), and Gaucher's disease are significant health concerns.
Existing treatments may have limitations or side effects.

Purpose of the Study:

To review the efficacy and safety of novel therapeutic agents for these conditions.
To provide an overview of recent advancements in treatment options.

Main Methods:

Review of clinical trial data and prescribing information for Tazarotene (Fabior Foam).
Analysis of studies on estradiol valerate and estradiol valerate/dienogest (Natazia) for HMB.
Examination of data for taliglucerase alfa (Elelyso) in Gaucher's disease treatment.

Main Results:

Tazarotene demonstrates efficacy in managing acne vulgaris.
Estradiol valerate and combination therapy show promise in reducing heavy menstrual bleeding.
Taliglucerase alfa provides a therapeutic option for Gaucher's disease.

Conclusions:

These agents represent important new therapeutic options for patients.
Further research may explore long-term outcomes and comparative effectiveness.